Molina Healthcare has confirmed, in its own securities filings, that it booked a $93 million impairment charge for a single decision: leaving its traditional Medicare Advantage Prescription Drug plans once the 2027 plan year begins. The company repeated the same exit plan three months later in its second-quarter earnings, when the discontinued drug product was still weighing on its 2026 guidance. For anyone currently enrolled in one of the affected Molina plans, what happens at the mailbox this fall matters more than the accounting entry: a notice that the current plan will not be offered again.
The $93 Million Impairment Charge Behind Molina’s Exit
Molina’s Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission, lays out the decision in plain accounting language: the company determined in February 2026 that its Medicare Advantage Prescription Drug product, known as MAPD, no longer matched its strategy, and it impaired the remaining intangible assets tied to that product during the first quarter.
The 10-Q breaks the $93 million into three pieces: $62 million in contract rights and licenses, $27 million in trade name value, and $4 million tied to provider networks, the accounting value Molina had built around a product it is now retiring rather than trying to fix.
Those intangible assets existed in the first place because Molina, like other insurers, has to renew a Medicare Advantage-Part D contract with the Centers for Medicare and Medicaid Services every year, and the contract rights and licenses on its books reflected the value of running that annual CMS relationship. Choosing not to renew it for 2027 is what triggered the write-down, rather than any change forced on Molina by CMS itself.
Free plan-change checklist: A Medicare plan can change its costs, drugs and doctors for next year even when its name stays the same. Check the changes with the free 2027 review sheet.
Free download from RetireShield. Getting it also signs you up for the free Retirement Money Brief, a weekday email. Unsubscribe anytime.
Why Molina Is Giving Up a $1 Billion Drug Plan Business
Molina disclosed the plan in a February 5, 2026 investor release, which put the MAPD product’s annual premium at approximately $1 billion and said the business did not align with the company’s shift toward serving dual-eligible Medicare members, people who qualify for both Medicare and Medicaid, a segment the release valued at about $5 billion in premium to Molina.
Molina’s broader Medicare segment, which includes the dual-eligible business it is keeping, covered about 224,000 people as of June 30, 2026, according to the company’s own reporting. MAPD enrollees are the subset of that population whose current drug coverage will not carry into 2027.
The February release tied the shift to a growing list of state contracts Molina already has lined up: it cited newly awarded Medicare Duals contracts in Idaho, Illinois, Massachusetts, Michigan and Ohio as part of the earnings it expects the dual-eligible business to add between 2027 and 2029, on top of the roughly $5 billion in premium the segment already generates.
The Exit Is Still on the Books Three Months Later
The decision was not a one-quarter announcement that quietly disappeared. Molina’s second-quarter 2026 earnings release, published July 22, 2026, restates that its full-year guidance includes a loss of $1.00 per share tied to “the traditional MAPD product, which the Company previously announced it will exit for 2027,” language that matches the February filing on the timeline.
That repetition matters for anyone waiting to see whether Molina reverses course. As of its most recent quarterly report, the company has signaled no change to the plan, and the $93 million impairment already sits on its books as a completed accounting entry rather than a proposal still under review.
The dollar impact has been consistent across both releases. In February, Molina said its 2026 guidance was burdened by $2.50 per diluted share, split between $1.50 for a new Florida Medicaid contract and $1.00 for the underperforming MAPD product it planned to exit. By July, the company had raised its full-year adjusted earnings guidance to at least $5.25 per share, but kept the same $1.00-per-share MAPD drag in place, alongside the $1.50-per-share hit tied to the Florida contract launch.
What Molina’s Medicare Advantage Members Face During Fall Open Enrollment
The timing lines up with the annual window when Medicare allows coverage changes for the coming plan year. Medicare’s Open Enrollment period runs from October 15 through December 7, and a plan must receive an enrollment request by December 7 for the change to take effect January 1.
Anyone in a Molina Medicare Advantage plan with drug coverage tied to the discontinued MAPD line needs to use that window to line up a replacement, whether a different Medicare Advantage plan with drug coverage, a standalone Medicare drug plan paired with Original Medicare, or another insurer’s offering, since Medicare does not automatically move an enrollee into comparable coverage once a specific plan is retired.
The 10-Q describes MAPD contracts with CMS as running for terms of one to three years, which is why some Molina members are only now finding out their plan will not continue past 2026 even though the company’s own decision was made back in February. That gap between when Molina decided and when a member’s plan formally ends is exactly the stretch the fall Open Enrollment window is meant to close.
Comparing Replacement Plans After Molina’s MAPD Exit
Molina’s exit leaves the comparison work to the people currently covered under the plan, since the SEC filings that confirm the write-off say nothing about which replacement fits a particular set of prescriptions, pharmacies or doctors. The Medicare Open Enrollment window is when that comparison has to happen, yet nothing in Molina’s own paperwork lines that window up against an individual member’s drugs or provider network.
The 2027 Medicare Open Enrollment Decision Kit is a 42-page decision kit built around a cost calculator spreadsheet that compares plans on cost, drugs and doctors, along with a prescription-by-plan comparison and a provider call script for checking whether a doctor is still in-network.
See The 2027 Medicare Open Enrollment Decision Kit.
AI-assisted research and drafting; reviewed by an editor.
